Owens & Minor (OMI)
(Delayed Data from NYSE)
$16.48 USD
+1.17 (7.64%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $16.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.48 USD
+1.17 (7.64%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $16.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Zacks News
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Owens & Minor (OMI) Q2 Earnings Expected to Decline
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Owens & Minor (OMI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.
Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 24.68% and 3.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is GN Store Nord (GNNDY) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.
Earnings Preview: Owens & Minor (OMI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints
by Zacks Equity Research
Koninklijke Philips' (PHG) Q1 top- and bottom-line results reflect negative impact of supply chain constraints and consequences of the Respironics field action.
Here's Why You Should Retain Integra (IART) Stock For Now
by Zacks Equity Research
Investors are optimistic about Integra (IART), given the strength in its CSS arm and notable product launches.
Here's Why You Should Hold on to Illumina (ILMN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.
Patterson Companies (PDCO) Moves Up 12.5%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) robust segmental performance and strong prospects in the dental space.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.
Here's Why You Should Hold on to Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.
Has Owens & Minor (OMI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Owens & Minor (OMI) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Illumina (ILMN) Hurt by Rising Costs, Tough Competition
by Zacks Equity Research
Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.
NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up
by Zacks Equity Research
NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.
Here's Why You Should Hold on to Cardiovascular Systems (CSII)
by Zacks Equity Research
Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.
IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists
by Zacks Equity Research
IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.
Here's Why You Should Retain Thermo Fisher (TMO) For Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.
Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space
by Zacks Equity Research
Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.
Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth
by Zacks Equity Research
In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.
STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.
Here's Why You Should Retain Charles River (CRL) Stock For Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.